Opus Genetics (NASDAQ:IRD) Stock Rating Lowered by Zacks Research

Opus Genetics (NASDAQ:IRD) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Chardan Capital boosted their price objective on Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Lifesci Capital upgraded Opus Genetics to a “strong-buy” rating in a report on Thursday, February 12th. BTIG Research boosted their price objective on Opus Genetics from $7.00 to $12.00 and gave the company a “buy” rating in a report on Monday, March 2nd. B. Riley Financial restated a “buy” rating on shares of Opus Genetics in a report on Thursday, April 30th. Finally, Wedbush boosted their price objective on Opus Genetics from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

Opus Genetics Stock Performance

Shares of Opus Genetics stock opened at $5.03 on Tuesday. The stock has a market cap of $359.15 million, a price-to-earnings ratio of -3.78 and a beta of 0.62. The stock has a 50 day moving average price of $4.97 and a 200-day moving average price of $3.31. Opus Genetics has a one year low of $0.90 and a one year high of $5.81.

Opus Genetics (NASDAQ:IRD) last announced its earnings results on Tuesday, May 12th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.59). Opus Genetics had a negative return on equity of 709.20% and a negative net margin of 892.36%.The company had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $2.93 million. Sell-side analysts predict that Opus Genetics will post -0.57 earnings per share for the current fiscal year.

Insider Transactions at Opus Genetics

In other Opus Genetics news, CEO George Magrath sold 9,511 shares of Opus Genetics stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.22, for a total transaction of $49,647.42. Following the completion of the sale, the chief executive officer directly owned 1,741,344 shares of the company’s stock, valued at $9,089,815.68. The trade was a 0.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ashwath Jayagopal sold 7,542 shares of Opus Genetics stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total value of $39,142.98. Following the sale, the insider directly owned 509,233 shares of the company’s stock, valued at approximately $2,642,919.27. This trade represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 73,395 shares of company stock valued at $382,278. Company insiders own 11.70% of the company’s stock.

Institutional Investors Weigh In On Opus Genetics

A number of institutional investors and hedge funds have recently bought and sold shares of IRD. Comerica Bank bought a new stake in Opus Genetics during the 1st quarter valued at $29,000. Royal Bank of Canada bought a new stake in Opus Genetics during the 1st quarter valued at $299,000. Nantahala Capital Management LLC raised its position in Opus Genetics by 6.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company’s stock valued at $3,152,000 after purchasing an additional 188,028 shares in the last quarter. Mink Brook Asset Management LLC raised its position in Opus Genetics by 47.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 1,197,616 shares of the company’s stock valued at $1,128,000 after purchasing an additional 387,536 shares in the last quarter. Finally, Opaleye Management Inc. raised its position in Opus Genetics by 3.8% during the 2nd quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company’s stock valued at $1,149,000 after purchasing an additional 45,000 shares in the last quarter. 14.97% of the stock is owned by institutional investors.

Opus Genetics News Roundup

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics announced it will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, which could help keep investor attention on the stock and provide a near-term catalyst. Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
• Positive Sentiment: The company said its cash runway into 2029 should fund several clinical milestones, including data readouts and program advancement, which supports the long-term investment case. Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
• Neutral Sentiment: Analysts at Citizens JMP lowered their price target to $11 from $12 but kept a “market outperform” rating, suggesting continued optimism despite a modest valuation reset.
• Neutral Sentiment: Lifesci Capital cut earnings estimates for Q2, Q3, Q4 and FY2026, but maintained a “Strong-Buy” rating, indicating the revisions were more about near-term losses than a change in the longer-term outlook.
• Negative Sentiment: Opus Genetics reported a wider-than-expected first-quarter loss of $0.75 per share versus expectations for a $0.16 loss, which is the clearest reason the stock is being sold today. Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Revenue came in at just $2.16 million, and the company continues to post large losses and negative margins, reinforcing concerns about profitability in the near term.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.